SAB Biotherapeutics (SABS) Appoints Jay Skyler to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise over 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 6, 2024 7:15 AM EDTMIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the Company or SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the companys Board of Directors.
Dr. Skylers appointment to our Board of Directors is a major milestone for SAB, said Samuel J. Reich, SABs chairman and Chief Executive Officer. His deep expertise in type 1 diabetes research and leadership in the... More
